GRACEcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

Dr. Jack West, Swedish Cancer Institute, discusses current trials seeking to determine the efficacy of combining immunotherapy agents in lung cancer.

Direct download: GRACEcast-526_Lung_West_Immunotherapy_Combinations.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of lung cancer, alone or in combination with chemotherapy.

Direct download: GRACEcast-525_Lung_West_Immunotherapy_First_Line_Treatment.mp4
Category:Lung-Cancer-Video -- posted at: 3:42pm PST

Dr. Jed Gorden, Swedish Cancer Institute, reviews the lung cancer screening process, including low-dose CT scanning, smoking cessation, follow-up testing and counseling, and describes the potential benefits.


Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in diagnosis and staging.

Direct download: GRACEcast-523_GCVL_LU_Bronchoscopy_EBUS.mp4
Category:Lung-Cancer-Video -- posted at: 7:59pm PST

Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.

Direct download: GRACEcast-522_Lung_West_Maintenance_Therapy_Advanced_NSCLC.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.


Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.


Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.


Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.

Direct download: GRACEcast-518_GCVL_LU_Histology_Specific_Regimens_Squamous.mp4
Category:Lung-Cancer-Video -- posted at: 7:29pm PST

Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.


Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.

Direct download: GRACEcast-516_GCVL_LU_Bevacizumab_Role_Stage_IV_NSCLC.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC patients.


Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.


Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.


Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.


Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.


Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.

Direct download: GRACEcast-510_GCVL_LU_ROS-1_Rearrangements_Defined.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them.

Direct download: GRACEcast-509_GCVL_LU_ALK_Rearrangements_What_Who.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Ross Camidge, University of Colorado, discusses the potential benefits as well as the disadvantages of multiplex mutation testing.


Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.

Direct download: GRACEcast-507_GCVL_LU_Targeted_Therapy_Post-Resection.mp4
Category:Lung-Cancer-Video -- posted at: 7:42pm PST

Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.

Direct download: GRACEcast-506_GCVL_LU_Standard_Adjuvant_Chemotherapy_Regimen.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Heather Wakelee, Stanford University Medical Center, discusses the purpose of adjuvant chemotherapy, and which patients benefit most from it.